In summary, these evidences showed that the alterations in monoamine metabolism, impaired neuroendocrine function, and plasma biomarkers are the major aetiological pathways for IFN-induced neuropsychiatric symptoms in patients with CH-C, which may be helpful to improve the management of HCV patients receiving antiviral treatment and illuminate the IFN-induced depression. Here, IFNA1 is linked to depressive symptom measurement.